DKK-1 antibodies
AssigneeEli Lilly and Company
InventorsMarcio Chedid, Ryan James Darling, Rachelle Jeanette Galvin, Barbara Anne Swanson
Life of this patent
Estimating the term…
Abstract
The invention provides human engineered antibodies, antigen-binding fragments thereof, that bind to, and inhibit the activity of, human DKK-1, and which are effective in treating diseases in which pathogenesis is mediated by DKK-1.
Claims14
A human engineered DKK-1 antibody or antigen binding fragment thereof, comprising a light chain variable region (LCVR) and a heavy chain variable region (HCVR), wherein the LCVR comprises complementarity determining regions (CDRs) LCDR1, LCDR2, and LCDR3 and the HCVR comprises CDRs HCDR1, HCDR2 and HCDR3, wherein LCDR1 has the amino sequence of SEQ ID NO:5, LCDR2 has the amino sequence of SEQ ID NO:47, LCDR3 has the amino sequence of SEQ ID NO:49, HCDR1 has the amino sequence of SEQ ID NO:1, HCDR2 has the amino sequence of SEQ ID NO:2, and an HCDR3 has the amino sequence of SEQ ID NO:44.
A human engineered DKK-1 antibody comprising two light chains wherein each light chain comprises the amino acid sequence of SEQ ID NO:
- 20, and two heavy chains wherein each heavy chain comprises the amino acid sequence of SEQ ID NO:
- 18.
Dependencies are inferred from the claim text.